Panacea Biotec Ltd

Panacea Biotec Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Panacea Biotec Ltd

₹ 535 0.50%
18 Jun - close price
panaceabiotec.com BSE: 531349 NSE: PANACEABIO
About

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]

Key Points

Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix

Website BSE NSE
  • Market Cap ₹ 3,276 Cr.
  • Current Price ₹ 535
  • High / Low ₹ 648 / 292
  • Stock P/E
  • Book Value ₹ 136
  • Dividend Yield 0.00 %
  • ROCE -2.44 %
  • ROE -2.36 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 3.93 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 0.47% over past five years.
  • Company has a low return on equity of -3.48% over last 3 years.
  • Earnings include an other income of Rs.36.4 Cr.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
128.93 129.19 143.02 150.50 136.46 115.72 147.35 163.49 132.53 166.70 141.13 165.19 166.75
134.60 139.50 146.58 150.65 142.50 129.71 140.35 155.53 159.41 167.88 158.92 153.45 164.18
Operating Profit -5.67 -10.31 -3.56 -0.15 -6.04 -13.99 7.00 7.96 -26.88 -1.18 -17.79 11.74 2.57
OPM % -4.40% -7.98% -2.49% -0.10% -4.43% -12.09% 4.75% 4.87% -20.28% -0.71% -12.61% 7.11% 1.54%
34.44 33.82 6.00 8.46 13.55 6.54 7.42 6.39 36.30 16.99 9.10 5.05 5.26
Interest 1.05 1.00 0.91 0.85 0.82 0.87 0.98 0.99 1.04 0.86 2.14 1.85 1.20
Depreciation 9.51 9.48 9.31 9.11 8.81 8.73 8.68 8.98 8.42 8.39 8.34 8.45 7.88
Profit before tax 18.21 13.03 -7.78 -1.65 -2.12 -17.05 4.76 4.38 -0.04 6.56 -19.17 6.49 -1.25
Tax % 169.63% 15.73% 6.56% 33.33% -6.13% -6.86% 1.05% -1.37% 4,875.00% 39.63% -26.92% 40.06% -20.00%
-12.68 10.98 -8.29 -2.20 -1.99 -15.88 4.71 4.44 -1.99 3.96 -14.01 3.89 -1.00
EPS in Rs -2.07 1.79 -1.35 -0.37 -0.32 -2.58 0.78 0.74 -0.31 0.66 -2.27 0.65 0.08
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
687 653 544 593 457 544 625 661 460 559 559 640
643 541 505 509 591 484 548 674 558 579 584 644
Operating Profit 44 112 39 84 -134 60 77 -13 -98 -20 -25 -5
OPM % 6% 17% 7% 14% -29% 11% 12% -2% -21% -4% -4% -1%
28 70 62 8 338 -21 9 1,687 154 62 55 36
Interest 105 127 101 101 105 174 185 181 4 4 4 6
Depreciation 67 73 68 57 54 43 46 44 39 37 35 33
Profit before tax -99 -19 -67 -66 45 -178 -146 1,449 13 1 -8 -7
Tax % 3% 10% -16% 15% 17% 9% 1% 26% 363% 201% 10% -3%
-108 -21 -56 -76 38 -194 -148 1,078 -34 -2 -9 -7
EPS in Rs -17.38 -2.98 -8.89 -12.07 6.15 -31.69 -24.09 175.91 -5.42 -0.19 -1.37 -0.88
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 0%
5 Years: 0%
3 Years: 12%
TTM: 14%
Compounded Profit Growth
10 Years: 5%
5 Years: 13%
3 Years: 21%
TTM: 52%
Stock Price CAGR
10 Years: 17%
5 Years: 8%
3 Years: 60%
1 Year: 26%
Return on Equity
10 Years: %
5 Years: -10%
3 Years: -3%
Last Year: -2%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 6 6 6 6 6 6 6 6 6 6 6 6
Reserves 449 426 350 303 344 193 -235 871 837 836 829 829
1,111 1,105 994 941 646 742 820 34 20 21 22 24
364 317 440 349 379 449 587 848 407 378 433 404
Total Liabilities 1,930 1,854 1,789 1,598 1,376 1,390 1,178 1,759 1,271 1,241 1,290 1,262
1,144 1,071 1,001 949 806 657 609 622 600 582 567 620
CWIP 155 161 30 40 23 24 34 17 42 102 128 100
Investments 15 9 7 7 5 6 0 5 13 40 3 10
616 614 750 602 542 703 534 1,114 615 517 592 532
Total Assets 1,930 1,854 1,789 1,598 1,376 1,390 1,178 1,759 1,271 1,241 1,290 1,262

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
37 91 131 118 105 -30 107 -108 -422 -0 -27 17
-37 16 -26 55 -6 -35 -48 1,283 430 10 65 -40
-1 -117 -107 -164 -101 91 -47 -1,176 -18 -3 -3 -1
Net Cash Flow -1 -10 -2 9 -2 26 12 -2 -10 7 35 -25
Free Cash Flow 30 85 107 103 100 -21 89 -119 -424 -71 -77 -37
CFO/OP 96% 64% 320% 146% -77% -36% 141% -2,235% 429% -12% 108% -496%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 52 79 95 84 71 46 49 45 48 37 47 42
Inventory Days 404 516 770 651 173 344 311 296 292 282 391 251
Days Payable 272 318 607 540 572 463 440 327 256 244 413 247
Cash Conversion Cycle 184 278 259 195 -328 -73 -80 14 83 76 25 46
Working Capital Days -126 27 -46 -96 -363 93 -43 -229 -5 -2 44 57
ROCE % 0% 4% 2% 3% -16% 5% 5% -6% -10% -4% -5% -2%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Active Patents (Global)
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of R&D Scientists
Number
Distribution Network - Vaccine Distributors
Number
Field Force Size (Sales & Marketing Staff)
Number
Distribution Network - Pharma Distributors
Number
Market Share - Tacrolimus (PanGraf)
%
Market Share - Transplant & Immunology Segment
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

23 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
73.59% 73.59% 73.59% 73.59% 73.47% 72.87% 72.49% 72.48% 72.48% 72.48% 72.48% 72.48%
0.22% 0.26% 0.26% 0.27% 0.26% 0.37% 0.38% 1.16% 0.79% 1.06% 1.36% 1.60%
0.54% 0.57% 0.69% 0.84% 1.07% 1.16% 1.16% 1.49% 1.52% 1.80% 1.85% 1.96%
25.66% 25.58% 25.46% 25.30% 25.21% 25.60% 25.96% 24.86% 25.20% 24.65% 24.31% 23.96%
No. of Shareholders 47,81548,87847,09146,24245,51339,98235,44633,59334,25633,59334,59732,620

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Aug 2021
    Transcript
    AI Summary
    PPT
  • Jul 2021
    Transcript
    AI Summary
    PPT